China National Medicines (SHSE:600511) Beneish M-Score: -2.06 (As of Jul. 04, 2026)


SHSE:600511 China National Medicines Corp Ltd SHSE:600511
86 GF Score
Price ¥26.94
GF Value ¥32.74
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China National Medicines Beneish M-Score?

China National Medicines SHSE:600511 +1.62% 86 Beneish M-Score is -2.06 as of Jul. 04, 2026. GuruFocus rates SHSE:600511 with a GF Score™ of 86/100 and a GF Value™ of ¥32.74 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 112 Medical Distribution companies, China National Medicines ranks worse than 75% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for China National Medicines's Beneish M-Score or its related term are showing as below:

SHSE:600511' s Beneish M-Score Range Over the Past 10 Years
Min: -2.59   Med: -2.25   Max: 0.63
Current: -2.06

During the past 13 years, the highest Beneish M-Score of China National Medicines was 0.63. The lowest was -2.59. And the median was -2.25.


China National Medicines Beneish M-Score Historical Data

* Premium members only.

The historical data trend for China National Medicines's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China National Medicines Beneish M-Score Chart

China National Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.40 -2.59 -2.49 -2.24 -2.33

China National Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -2.18 -2.07 -2.33 -2.06

SHSE:600511 vs MCK, CAH, COR: Beneish M-Score Comparison

For the Medical Distribution subindustry, China National Medicines's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Medicines Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Medicines's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China National Medicines's Beneish M-Score falls into.


SHSE:600511
86GF Score
China National Medicines Corp Ltd SHSE:600511
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Medicines Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China National Medicines for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0766+0.528 * 1.06+0.404 * 1.0387+0.892 * 1.0415+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8178+4.679 * 0.047161-0.327 * 0.9549
=-2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥18,108 Mil.
Revenue was 13555.32 + 13086.979 + 13747.351 + 12920.948 = ¥53,311 Mil.
Gross Profit was 826.727 + 961.003 + 925.361 + 770.699 = ¥3,484 Mil.
Total Current Assets was ¥31,311 Mil.
Total Assets was ¥36,176 Mil.
Property, Plant and Equipment(Net PPE) was ¥782 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥337 Mil.
Total Current Liabilities was ¥14,355 Mil.
Long-Term Debt & Capital Lease Obligation was ¥215 Mil.
Net Income was 474.264 + 504.328 + 543.718 + 489.532 = ¥2,012 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -3592.951 + 4055.95 + -539.998 + 382.741 = ¥306 Mil.
Total Receivables was ¥16,150 Mil.
Revenue was 12713.002 + 12568.91 + 13272.037 + 12634.36 = ¥51,188 Mil.
Gross Profit was 802.774 + 926.441 + 915.678 + 901.017 = ¥3,546 Mil.
Total Current Assets was ¥30,442 Mil.
Total Assets was ¥35,096 Mil.
Property, Plant and Equipment(Net PPE) was ¥840 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥396 Mil.
Total Current Liabilities was ¥14,549 Mil.
Long-Term Debt & Capital Lease Obligation was ¥252 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18108.051 / 53310.598) / (16150.408 / 51188.309)
=0.339671 / 0.31551
=1.0766

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3545.91 / 51188.309) / (3483.79 / 53310.598)
=0.069272 / 0.065349
=1.06

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (31311.243 + 782.134) / 36176.208) / (1 - (30442.472 + 840.475) / 35096.471)
=0.11286 / 0.108658
=1.0387

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=53310.598 / 51188.309
=1.0415

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 840.475)) / (0 / (0 + 782.134))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(337.272 / 53310.598) / (396.045 / 51188.309)
=0.006327 / 0.007737
=0.8178

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((214.572 + 14354.668) / 36176.208) / ((252.351 + 14549.467) / 35096.471)
=0.40273 / 0.421747
=0.9549

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2011.842 - 0 - 305.742) / 36176.208
=0.047161

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China National Medicines has a M-score of -2.06 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.06 mean?
China National Medicines (SHSE:600511) has a Beneish M-Score of -2.06 as of Jul. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on China National Medicines and its competitors. According to the industry distribution chart, China National Medicines ranks #84 out of 112 companies in the Medical Distribution industry, placing it in the top 75%.
Is China National Medicines' Beneish M-Score too high?
China National Medicines' current Beneish M-Score is -2.06. Based on the distribution chart, China National Medicines ranks #84 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, China National Medicines has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Beneish M-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #84 out of 112 companies for Beneish M-Score. This places China National Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on China National Medicines and its competitors. China National Medicines's current Beneish M-Score is -2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.74, compared to a current price of ¥26.94 — trading 17.7% below its estimated fair value. The current Beneish M-Score is -2.06. China National Medicines' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Beneish M-Score is -2.06 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.94 is trading 17.7% below its estimated GF Value™ of ¥32.74. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • Beneish M-Score: -2.06
  • GF Value™: ¥32.74 vs. price of ¥26.94 (17.7% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
86GF Score

Get the complete analysis for SHSE:600511

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.94
Price
¥32.74
GF Value